All In Biotech

Free tool

FAERS Monitor: Annovera

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209627 or its brand name (Annovera, Ethinyl Estradiol, Segesterone Acetate). Reports on generic versions are filed under their own applications.

Reports

383

Serious

75

20% of reports

Hospitalization

28

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • intermenstrual bleeding44
  • off label use36
  • vaginal haemorrhage36
  • nausea34
  • drug ineffective26
  • headache23
  • vaginal discharge18
  • vomiting17
  • device expulsion15
  • pulmonary embolism13
  • depression12
  • metrorrhagia12
  • migraine12
  • abdominal pain11
  • dysmenorrhoea11

Reports by year received

View as table
YearReports
20191
202057
202186
202287
202338
202430
202552
202632

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,776 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intermenstrual bleedingSignal44435.8329.618,513
vaginal dischargeSignal1897.862.31,628
dysmenorrhoeaSignal1145.625.5436
vaginal haemorrhageSignal3645.633.41,527
metrorrhagiaSignal1238.722.2404
device expulsionSignal1512.77.7151
pulmonary embolismSignal137.54.467
migraineSignal126.94.055
depressionSignal122.91.713
abdominal painSignal112.61.59
nauseaSignal342.41.726
off label useSignal362.31.725
headacheSignal232.01.411
vomiting172.01.28
drug ineffective261.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.